Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular Genomics for Translational Research in Cancer
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Genomics for Translational Research in Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 3864

Special Issue Editor

Dr. Ioana Berindan-Neagoe

E-Mail Website
Guest Editor
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400372 Cluj-Napoca, Romania
Interests: microRNAs; biomarkers; apoptosis; cancer profiling; immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advancements in molecular sciences enabled the development of new potent therapies, as well as new comprehensive diagnostic means for cancer patients, which translate to better prognosis. From targeted therapies and immunotherapy to new horizons such as gene profiling, gene editing and the potential applicability of non-coding RNAs as therapeutic, diagnostic and prognostic tools, the constant discovery of molecular targets and mechanisms help to shape the future of oncology. As we begin to grasp the importance of genomic medicine in understanding the pathogenesis and progression of cancer, new discoveries within this field have already been made. The advancements made in genomics proved that there is a special need to offer in-depth diagnosis for cancer patients, with the purpose of providing a customized and an on-point treatment plan, thus increasing survival. This Special Issue is dedicated to all researchers and physicians who work in the field of cancer and endeavor to ultimately provide patients with faster, more accurate diagnosis and more effective treatment, as well as better care.

This Special Issue is supervised by Prof. Dr. Ioana Berindan-Neagoe (Iuliu Hatieganu University of Medicine and Pharmacy) and assisted by our Topical Advisory Panel Member Dr. Alexandru Tirpe (Institute of Oncology and Iuliu Hatieganu University of Medicine and Pharmacy).

Dr. Ioana Berindan-Neagoe
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • translational medicine
  • genomics
  • diagnostics and prognostics
  • targeted therapy
  • immunotherapy
  • non-coding RNAs
  • tumor microenvironment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 2376 KiB  
Article
On the Boundary of Exploratory Genomics and Translation in Sequential Glioblastoma
by Marton Tompa, Bence Galik, Peter Urban, Bela Istvan Kajtar, Zoltan Kraboth, Attila Gyenesei, Attila Miseta and Bernadette Kalman
Int. J. Mol. Sci. 2024, 25(14), 7564; https://doi.org/10.3390/ijms25147564 - 10 Jul 2024
Cited by 2 | Viewed by 953
Abstract
OMICS methods brought significant advancements to the understanding of tumor cell biology, which transformed the treatment and prognosis of several cancers. Clinical practice and outcomes, however, changed significantly less in the case of glioblastoma (GBM). In this study, we aimed to assess the [...] Read more.
OMICS methods brought significant advancements to the understanding of tumor cell biology, which transformed the treatment and prognosis of several cancers. Clinical practice and outcomes, however, changed significantly less in the case of glioblastoma (GBM). In this study, we aimed to assess the utility of whole exome (WES) sequencing in the clinical setting. Ten pairs of formalin-fixed, paraffin-embedded (FFPE) GBM specimens were obtained at onset (GBM-P) and at recurrence (GBM-R). Histopathological and molecular features of all samples supported the diagnosis of GBM based on WHO CNS5. WES data were filtered, applying a strict and custom-made pipeline, and occurrence of oncogenic and likely oncogenic variants in GBM-P, GBM-R or both were identified by using the VarSeq program version 2.5.0 (Golden Helix, Inc.). Characteristics and recurrence of the variants were analyzed in our own cohort and were also compared to those available in the COSMIC database. The lists of oncogenic and likely oncogenic variants corresponded to those identified in other studies. The average number of these variants were 4 and 5 out of all detected 24 and 34 variants in GBM-P and GBM-R samples, respectively. On average, one shared oncogenic/likely oncogenic variant was found in the pairs. We assessed the identified variants’ therapeutic significance, also taking into consideration the guidelines by the Association for Molecular Pathology (AMP). Our data support that a thorough WES analysis is suitable for identifying oncogenic and likely oncogenic variants in an individual clinical sample or a small cohort of FFPE glioma specimens, which concur with those of comprehensive research studies. Such analyses also allow us to monitor molecular dynamics of sequential GBM. In addition, careful evaluation of data according to the AMP guideline reveal that though therapeutic applicability of the variants is generally limited in the clinic, such information may be valuable in selected cases, and can support innovative preclinical and clinical trials. Full article
(This article belongs to the Special Issue Molecular Genomics for Translational Research in Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1554 KiB  
Review
The Glioblastoma CircularRNAome
by Alexandru Tirpe, Cristian Streianu, Stefana Maria Tirpe, Anja Kocijancic, Radu Pirlog, Bianca Pirlog, Constantin Busuioc, Ovidiu-Laurean Pop and Ioana Berindan-Neagoe
Int. J. Mol. Sci. 2023, 24(19), 14545; https://doi.org/10.3390/ijms241914545 - 26 Sep 2023
Cited by 6 | Viewed by 2103
Abstract
Glioblastoma remains one of the most aggressive cancers of the brain, warranting new methods for early diagnosis and more efficient treatment options. Circular RNAs (circRNAs) are rather new entities with increased stability compared to their linear counterparts that interact with proteins and act [...] Read more.
Glioblastoma remains one of the most aggressive cancers of the brain, warranting new methods for early diagnosis and more efficient treatment options. Circular RNAs (circRNAs) are rather new entities with increased stability compared to their linear counterparts that interact with proteins and act as microRNA sponges, among other functions. Herein, we provide a critical overview of the recently described glioblastoma-related circRNAs in the literature, focusing on their roles on glioblastoma cancer cell proliferation, survival, migration, invasion and metastasis, metabolic reprogramming, and therapeutic resistance. The main roles of circRNAs in regulating cancer processes are due to their regulatory roles in essential oncogenic pathways, including MAPK, PI3K/AKT/mTOR, and Wnt, which are influenced by various circRNAs. The present work pictures the wide implication of circRNAs in glioblastoma, thus highlighting their potential as future biomarkers and therapeutic targets/agents. Full article
(This article belongs to the Special Issue Molecular Genomics for Translational Research in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop